Mitochondrial Dysfunction in Parkinson's Disease

Parkinson's disease is characterised by progressive loss of dopaminergic neurons in the substantia nigra, leading to hallmark motor and non-motor symptoms. A substantial body of evidence implicates mitochondrial dysfunction as a central driver of neurodegeneration. Impairments in the electron transport chain, particularly complex I deficiency, diminish ATP production and promote oxidative stress. Concurrently, disruptions in mitochondrial DNA homeostasis reduce the pool of functional genomes, further compromising bioenergetic capacity. Defective quality-control mechanisms, including mitophagy, hinder the removal of damaged mitochondria, allowing accumulation of reactive oxygen species that damage proteins, lipids and nucleic acids. Altered iron handling and oxidative damage exacerbate these deficits, while genetic mutations in mitochondrial-associated genes such as PINK1, Parkin and SNCA highlight the interplay between inherited and sporadic forms of the disease. Understanding these mitochondrial pathways is essential to unravelling Parkinson’s pathogenesis and developing targeted interventions.

Research from Nature Portfolio

Recent studies have shown that idiopathic Parkinson’s disease can be stratified by the severity of neuronal respiratory complex I deficiency. One investigation identified two molecular subtypes: a widespread complex I-deficient subtype with extensive mitochondrial DNA deletions and non-tremor-dominant symptoms, and a subtype with region-restricted dysfunction and tremor-dominant presentation. This stratification offers a route to precision therapies targeting bioenergetic failure. Foundational research has also revealed that neurons in the substantia nigra of patients fail to upregulate mitochondrial DNA copy number in response to deletion burden, leading to depletion of wild-type genomes. This failure in mitochondrial DNA homeostasis underlines a key mechanism underpinning neuronal vulnerability and may guide future strategies to bolster genome maintenance.

Mitochondrial Dysfunction in Parkinson's Disease publication trend

The graph below shows the total number of articles in mitochondrial dysfunction in parkinson's disease across all publications each year (not limited to Nature Index journals).

Technical terms

Electron transport chain (ETC): A series of protein complexes in the inner mitochondrial membrane responsible for oxidative phosphorylation and ATP synthesis.

Complex I: The first enzyme of the ETC, NADH:ubiquinone oxidoreductase, often impaired in Parkinson’s disease, reducing cellular energy output.

Mitophagy: The selective autophagic removal of damaged mitochondria to maintain cellular quality control and prevent oxidative damage.

mtDNA (mitochondrial DNA): The circular genome within mitochondria encoding essential respiratory-chain components; its deletions and copy-number alterations impact bioenergetics.

Oxidative stress: An imbalance between reactive oxygen species production and antioxidant defences, leading to cellular damage and dysfunction.

Dopaminergic neuron: A neuron synthesising and releasing dopamine, highly susceptible to mitochondrial dysfunction in Parkinson’s disease.

References

1. Mitochondrial dysfunction in Parkinson’s disease – a key disease hallmark with therapeutic potential. Molecular Neurodegeneration (2023).
2. Mitochondrial complex I deficiency stratifies idiopathic Parkinson’s disease. Nature Communications (2024).
3. Defective mitochondrial DNA homeostasis in the substantia nigra in Parkinson disease. Nature Communications (2016).
4. Mitochondrial DNA damage triggers spread of Parkinson’s disease-like pathology. Molecular Psychiatry (2023).
5. Parkinson’s disease neurons exhibit alterations in mitochondrial quality control proteins. npj Parkinson's Disease (2023).
6. Dopamine‑iron homeostasis interaction rescues mitochondrial fitness in Parkinson's disease. Neurobiology of Disease (2024).